Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy

[1]  W. Scheithauer,et al.  Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Ying Cheng,et al.  Anlotinib monotherapy for refractory metastatic colorectal cancer: A double-blinded, placebo controlled, randomized Phase III trial (ALTER0703). , 2021, The oncologist.

[3]  Y. Liu,et al.  Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study , 2021, British Journal of Cancer.

[4]  Yuan Zhang,et al.  Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial , 2021, Clinical Cancer Research.

[5]  D. Schrag,et al.  Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. , 2021, JAMA.

[6]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[7]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[8]  A. Grothey.  Pembrolizumab in MSI-H-dMMR Advanced Colorectal Cancer - A New Standard of Care. , 2020, The New England journal of medicine.

[9]  Y. Shu,et al.  Combination of anlotinib and irinotecan in the second-line treatment of patients with advanced colorectal cancer: An open-label, multicenter phase I/II study. , 2020 .

[10]  U. Teichgräber,et al.  Peripherally inserted central venous catheter (PICC) in outpatient and inpatient oncological treatment , 2020, Supportive Care in Cancer.

[11]  Ying Cheng,et al.  Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial. , 2019, The oncologist.

[12]  G. Pollara,et al.  Intravenous catheter-related adverse events exceed drug-related adverse events in outpatient parenteral antimicrobial therapy , 2018, The Journal of antimicrobial chemotherapy.

[13]  Ying Cheng,et al.  Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial , 2018, JAMA oncology.

[14]  Yahiya Y. Syed.  Anlotinib: First Global Approval , 2018, Drugs.

[15]  F. Du,et al.  Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma , 2018, Clinical Cancer Research.

[16]  N. Lu,et al.  Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. , 2018, Gene.

[17]  Publisher's Note , 2018, Anaesthesia.

[18]  J. Meyerhardt,et al.  Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial , 2017, JAMA.

[19]  J Ricke,et al.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  R. Xu,et al.  Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  M. Ando,et al.  Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  B. Xiong,et al.  XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis , 2016, Cancer investigation.

[23]  A. Hinke,et al.  Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[24]  G. Fontanini,et al.  FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. , 2015, The Lancet. Oncology.

[25]  C. Punt,et al.  Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group , 2015, The Lancet.

[26]  E. Van Cutsem,et al.  Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. , 2015, European journal of cancer.

[27]  Jianming Xu,et al.  Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Carrato,et al.  Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Salazar,et al.  Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Y. Ba,et al.  Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. , 2011, Chinese journal of cancer.

[31]  C. Bokemeyer,et al.  Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  D. Kerr,et al.  Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  T. Conroy,et al.  Capecitabine plus oxaliplatin (XELOX) versus 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) as first‐line treatment for metastatic colorectal cancer , 2011, International journal of cancer.

[34]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[35]  C. Bokemeyer,et al.  Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Wolzt,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.

[37]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.